Compare Adaptive Biotechnologies Corp (ADPT) vs VF Corp (VFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VF Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20 (market cap $3.33B), while VF Corp trades at $15.84 (market cap $6.45B). The key difference: VF Corp is the larger of the two by market cap, and VF Corp pays a 2.19% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | VFC | |
|---|---|---|
Market Cap | $3.33B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $21.55 |
52-Week Low | $10.24 | $11.66 |
Enterprise Value | $3.19B | $10.60B |
Dividend Yield | — | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
VFC trades at $16.45, up 0.92% on the day, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings showed a Q1 2026 miss after two prior beats, while revenue declined to $9.50B in 2025. The company maintains a solid gross margin of 54.78% but reported a net loss of $189.72M. Analyst consensus is mixed with a $20.00 price target, and news highlights focus on turnaround progress and debt reduction.
VFC's outlook hinges on executing its brand turnaround, particularly at Vans, with guided revenue growth for 2027 offering potential upside. Risks include weak consumer confidence and high leverage, though deleveraging efforts are underway. The stock presents a value opportunity with a low P/S of 0.68, but investors face near-term volatility from earnings uncertainty and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
